As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
10 Analysts have issued a Arbutus Biopharma Corporation forecast:
10 Analysts have issued a Arbutus Biopharma Corporation forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 15 15 |
53%
53%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -42 -42 |
48%
48%
|
|
| EBIT (Operating Income) EBIT | -43 -43 |
48%
48%
|
|
| Net Profit | -54 -54 |
30%
30%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
| Head office | Canada |
| CEO | Lindsay Androski |
| Employees | 44 |
| Founded | 2005 |
| Website | www.arbutusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


